ArticleFrontiers in endocrinology2022
Predictors of Malignancy in Thyroid Nodules Classified as Bethesda Category III.
Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Integrated Ultrasound Features, Cytologic Subclassification, and Systemic Inflammatory Markers for Predicting Malignancy in Bethesda III Thyroid Nodules.Journal of clinical medicine · 2026Article
- Surgical outcomes of Bethesda System for Reporting Thyroid Cytopathology diagnostic category class I, II, and III thyroid nodules.Frontiers in endocrinology · 2026Article
- Reinterpretation of the clinical and biological behaviors of papillary thyroid carcinoma subtypes within the 2022 WHO classification: a cross-sectional study of 768 cases.World journal of surgical oncology · 2025Article
- A Mixed Model of Clinical Characteristics, Strain Elastography and ACR-TIRADS Predicts Malignancy in Small Thyroid Nodules: A Prospective Single-Center Study.Medicina (Kaunas, Lithuania) · 2025Article
- Utility of the Clinical and Radiological Features in the Management of Bethesda 3 and 4 Thyroid Nodules.Indian journal of surgical oncology · 2025Article
- Article
- Risk of malignancy in thyroid nodules Bethesda III sub classification into nuclear atypia and architectural atypia.Saudi medical journal · 2025Article
- A model based on Chinese thyroid imaging reporting and data systems for predicting Bethesda III/IV thyroid nodules.Frontiers in endocrinology · 2025Article
- A Comprehensive Approach to the Thyroid Bethesda Category III (AUS) in the Transition Zone Between 2nd Edition and 3rd Edition of The Bethesda System for Reporting Thyroid Cytopathology: Subcategorization, Nuclear Scoring, and More.Endocrine pathology · 2024Article
- High Malignancy Risk and Its Predictors in South Indian Patients With Bethesda II Thyroid Nodules.Cureus · 2024Article
- Optimizing thyroid AUS nodules malignancy prediction: a comprehensive study of logistic regression and machine learning models.Frontiers in endocrinology · 2024Article
- The Role of "Critical" Ultrasound Reassessment in the Decision-Making of Bethesda III Thyroid Nodules.Medicina (Kaunas, Lithuania) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine predictors of malignancy in surgically treated Bethesda category III nodules.
methodsPatients with surgically treated thyroid nodules classified as Bethesda category III were retrospectively enrolled. The association between clinical/sonographic features and postoperative pathology was evaluated using univariate and multivariate analyses.
resultsA total of 188 nodules from 184 patients were included. The overall malignancy rate was 54.3%. In univariate analysis, male sex, aspect ratio >1, microcalcification, unclear boundary,
conclusionsMalignant disease was common in Bethesda category III nodules, and surgical treatment was strongly indicated in the presence of male sex, aspect ratio>1, microcalcification, and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.